This inventor holds 36 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Antibody Crystallization. Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC. Active years: 1992-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Shorthills, NJ (US) (2011)
- Montville, NJ (US) (1992 - 2021)
Company Filing History:
28 out of 1,829 
6 out of 2,405 
1 out of 67 Years Active: 1992-2026
Areas of Expertise:
Title: **The Innovative Contributions of Paul Reichert**
Introduction
Paul Reichert, based in Montville, NJ, is a prominent inventor known for his groundbreaking work in the field of monoclonal antibodies. With a total of 35 patents to his name, Reichert has made significant strides in the development of therapeutic solutions for various medical conditions, particularly in oncology and autoimmunity.
Latest Patents
Among his latest patents, Reichert has developed crystalline forms of anti-human PD-1 monoclonal antibodies, including pembrolizumab. This invention outlines methods for producing antibody crystals, which are instrumental in the treatment of cancers. The production process allows for the creation of crystals suitable for X-ray diffraction, leading to the determination of the three-dimensional structure of pembrolizumab at a resolution of 2.3 A.
Another notable patent focuses on crystalline anti-human IL-23p19 antibodies. This invention provides new forms of antibodies that can be utilized in the treatment of inflammatory and autoimmune disorders. With various methods of crystallization available, this innovation offers substantial improvements in stability, maintaining biological activity longer than traditional solution formulations.
Career Highlights
Reichert has been affiliated with major pharmaceutical companies, including Schering Corporation and Merck Sharp & Dohme Corporation. His work in these esteemed institutions has facilitated the advancement of novel therapeutic approaches and strengthened his expertise in antibody design and development.
Collaborations
Throughout his career, Reichert has collaborated with notable colleagues such as Vincent Stewart Madison and Alan W. Hruza. These collaborations have further enriched his innovations and contributed to significant breakthroughs in the field of immunotherapy.
Conclusion
Paul Reichert's extensive portfolio of patents and collaborations underscores his commitment to advancing medical science. Through his innovative work on monoclonal antibodies, he has not only contributed to essential cancer treatments but has also paved the way for future advancements in therapeutic interventions for a variety of diseases. His dedication to research and development continues to inspire the scientific community and has a lasting impact on patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile